Dexrazoxane has no impact on sensitivity of childhood leukemic blasts to daunorubicin

Leukemia

Volumn 16, Issue 5, 2002, Pages 820-825

  Styczynski, J ^a   Wysocki, M ^b   Balwierz, W ^b   Kowalczyk, J R ^c  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Daunorubicin; Dexrazoxane; Resistance; Sensitivity

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTHRACYCLINE DERIVATIVE; CARDIOXAN; DAUNORUBICIN; FREE RADICAL; LIPID; LIPOCORTIN 5; RAZOXANE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CARDIOTOXICITY; CELL CYCLE; CELL STRAIN HL 60; CELL STRAIN K 562; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SENSITIZATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; LEUKEMIA CELL LINE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION;

EID: 0036100143     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402474     Document Type: Article

References (16)

1. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells
2. Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin
3. Differential effect of dexrazoxane on the in vitro cytotoxicity of topoisomerase-II inhibitors by the cell type in childhood leukemias
4. In vitro drug resistance profiles in adult versus childhood acute lymphoblastic leukaemia
5. Mode of action of the cytostatic agent 'ICRF 159
6. Antineoplastic activity of continuous exposure to dexrazoxane: Potential new role as a novel topoisomerase II inhibitor
7. Bisdioxypiperazine, (+)-1, 2-Bis(3, 5-dioxypiperazinyl-1-yl)propane (ICRF 187), enhances the antiproliferative effect of cisplatin on human ovarian cancer cells
8. Clinical pharmacology of dexrazoxane
9. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor, of topoisomerase II
10. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis
11. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy
12. Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562
13. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells
14. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane
15. Dexrazoxane (ICRF-187)
16. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats